Ignite Creation Date:
2024-05-06 @ 12:35 PM
Last Modification Date:
2024-10-26 @ 1:01 PM
Study NCT ID:
NCT03798977
Status:
COMPLETED
Last Update Posted:
2024-02-06
First Post:
2018-12-27
Brief Title:
Preclinical Validation of New Anti-melanoma Compounds
Sponsor:
Centre Hospitalier Universitaire de Nice
Organization:
Centre Hospitalier Universitaire de Nice
Study Overview
Official Title:
Preclinical Validation of New Anti-melanoma Compounds Study on Patient Melanoma Cells Sensitive and Resistant to BRAFMEK Inhibitors
Status:
COMPLETED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ERMELATHER
Brief Summary:
This research program is in keeping with the chemistrybiologyclinical interface and gathers 4 teams with complementary expertise in these respective fields It will allow deciphering the mechanisms of action of new Thiazole-Benzenesulfonamide family TZB derivatives on metastatic melanoma sensitive and resistant to BRAF and MEK inhibitors Investigators will use melanoma cell lines and primary cells from patients to validate these compounds in collaboration with clinical team 2 and 4 In conclusion the investigators expect to establish the proof of concept that this new class of bioactive molecules first in class we developed in collaboration with Team 3 have the potential to go to the clinic for the treatment of highly aggressive cancers and particularly metastatic melanoma sensitive and resistant B-Raf and MEK inhibitors Furthermore the realization of this project can undoubtedly increase the knowledge of mechanisms and signaling pathways that are involved in resistant to BRAF and MEK inhibitors and allow the selection of drug candidates capable of restoring the sensitivity of these melanoma cells
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None